Thomas Bayer

Title: Thomas Bayer: Innovator in Antibody Research

Introduction

Thomas Bayer is a prominent inventor based in Göttingen, Germany. He has made significant contributions to the field of antibody research, particularly in the context of Alzheimer's disease. With a total of four patents to his name, Bayer's work focuses on developing innovative therapeutic solutions.

Latest Patents

One of his latest patents is for a humanised anti-n-truncated amyloid β monoclonal antibody. This invention relates to humanised antibodies that bind amyloid peptides, incorporating mutations in the heavy chain and/or light chain variable domains to enhance binding activity. These antibodies hold potential for treating Alzheimer's disease. Another notable patent is for conformational-specific antibodies against Aβ oligomers. This disclosure pertains to an antibody molecule that recognizes a conformational epitope of human trimeric or tetrameric Aβ oligomers, while not binding to human monomeric Aβ 1-42 or dimers. The patent also includes pharmaceutical and diagnostic compositions that utilize this antibody molecule.

Career Highlights

Throughout his career, Thomas Bayer has worked with several esteemed institutions. He has been associated with Georg-August-University Göttingen, Universitätsmedizin Göttingen, and Synaptic Systems GmbH, which focuses on neurobiological research and development.

Collaborations

Bayer has collaborated with notable colleagues, including Oliver Wirths and Henrik Martens. Their joint efforts have contributed to advancements in the field of antibody research.

Conclusion

Thomas Bayer's innovative work in antibody research has the potential to significantly impact the treatment of Alzheimer's disease. His patents reflect a commitment to advancing medical science and improving patient outcomes.